Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.

@article{Schwarzberg2007SelectiveLA,
  title={Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.},
  author={Abraham B. Schwarzberg and Elizabeth H Stover and Tanya P. Sengupta and A Lberto Michelini and Michele Vincitore and Lindsey Robert Baden and Matthew H. Kulke},
  journal={Cancer investigation},
  year={2007},
  volume={25 4},
  pages={
          249-55
        }
}
Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia. We evaluated the incidence of lymphopenia and opportunistic infections during treatment and up to 12 months following treatment discontinuation in a cohort of 39 patients receiving temozolomide for advanced neuroendocrine tumors. The incidence of Grade 3-4 lymphopenia was 46 percent after 4 months of therapy and remained at 30 percent or greater for 12… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Similar Papers

Loading similar papers…